% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Baertsch:176949,
      author       = {M.-A. Baertsch and M. Fougereau and T. Hielscher$^*$ and S.
                      Sauer and I. Breitkreutz and K. Jordan and C. Müller-Tidow
                      and H. Goldschmidt and M.-S. Raab$^*$ and J. Hillengass$^*$
                      and N. Giesen$^*$},
      title        = {{C}arfilzomib, {L}enalidomide, and {D}examethasone
                      {F}ollowed by {S}alvage {A}utologous {S}tem {C}ell
                      {T}ransplant with or without {M}aintenance for {R}elapsed or
                      {R}efractory {M}ultiple {M}yeloma.},
      journal      = {Cancers},
      volume       = {13},
      number       = {18},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2021-02189},
      pages        = {4706},
      year         = {2021},
      note         = {#LA:A360#},
      abstract     = {Salvage high-dose chemotherapy and autologous stem cell
                      transplantation (HDCT/ASCT) is a treatment option for
                      relapsed and/or refractory multiple myeloma (RRMM). No data
                      are available on salvage HDCT/ASCT following re-induction
                      treatment with state-of-the-art triplet regimens. We
                      retrospectively report on 44 patients receiving salvage
                      HDCT/ASCT following re-induction with
                      carfilzomib/lenalidomide/dexamethasone (KRd). All patients
                      received frontline HDCT/ASCT with median time to progression
                      (TTP1) of 2.9 (1.2-13.5) years, enabling paired comparison
                      of frontline and salvage HDCT/ASCT. After re-induction and
                      before salvage transplant, 25/44 patients $(57\%)$ attained
                      ≥ very good partial response (VGPR), which increased to
                      34/44 $(77\%)$ at best response after salvage HDCT/ASCT.
                      Median progression-free survival (PFS) was 23.3 months from
                      salvage HDCT/ASCT. Patients with ≥ VGPR at the time of
                      salvage HDCT/ASCT and those receiving maintenance treatment
                      post salvage HDCT/ASCT had significantly superior PFS
                      (hazard ratio (HR) 0.19, p = 0.001 and HR 0.20, p = 0.009).
                      In patients achieving at least an equal depth of response
                      before salvage HDCT/ASCT as before frontline HDCT/ASCT, PFS
                      after salvage HDCT/ASCT was comparable to the frontline
                      situation (p = 0.3). This is the first report of
                      state-of-the-art triplet re-induction and salvage HDCT/ASCT
                      for RRMM after frontline transplantation. Deep remissions
                      achieved with KRd translate into prolonged PFS following
                      salvage HDCT/ASCT and are enhanced by maintenance
                      treatment.},
      keywords     = {lenalidomide maintenance (Other) / multiple myeloma (Other)
                      / salvage autologous stem cell transplantation (Other) /
                      salvage high-dose chemotherapy (Other)},
      cin          = {C060 / A360},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)A360-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34572934},
      pmc          = {pmc:PMC8472377},
      doi          = {10.3390/cancers13184706},
      url          = {https://inrepo02.dkfz.de/record/176949},
}